Manuel Chaves-Conde

730 total citations
24 papers, 490 citations indexed

About

Manuel Chaves-Conde is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Manuel Chaves-Conde has authored 24 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Manuel Chaves-Conde's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (10 papers) and Gastric Cancer Management and Outcomes (5 papers). Manuel Chaves-Conde is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (10 papers) and Gastric Cancer Management and Outcomes (5 papers). Manuel Chaves-Conde collaborates with scholars based in Spain, Portugal and United States. Manuel Chaves-Conde's co-authors include Fernando Rivera, Enrique Aranda, Javier Sastre, Josep Tabernero, Eduardo Díaz‐Rubio, Amancio Carnero, Alfredo Carrato, Bernardo Queralt, Bartomeu Massutí and Jorge Aparicio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Manuel Chaves-Conde

22 papers receiving 479 citations

Peers

Manuel Chaves-Conde
М. В. Копп Russia
Jiansheng Li China
Quanren Wang China
Julian Adlard United Kingdom
Annett Maderer Germany
Jean Philippe Metges France
Lingzhi Hong United States
A Fujioka Japan
Tommasina Biscotti Italy
Soetkin Vlassak Germany
М. В. Копп Russia
Manuel Chaves-Conde
Citations per year, relative to Manuel Chaves-Conde Manuel Chaves-Conde (= 1×) peers М. В. Копп

Countries citing papers authored by Manuel Chaves-Conde

Since Specialization
Citations

This map shows the geographic impact of Manuel Chaves-Conde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Chaves-Conde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Chaves-Conde more than expected).

Fields of papers citing papers by Manuel Chaves-Conde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Chaves-Conde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Chaves-Conde. The network helps show where Manuel Chaves-Conde may publish in the future.

Co-authorship network of co-authors of Manuel Chaves-Conde

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Chaves-Conde. A scholar is included among the top collaborators of Manuel Chaves-Conde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Chaves-Conde. Manuel Chaves-Conde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cho, Byoung Chul, Irene Braña, Beatriz Cirauqui, et al.. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer. 23(S1). 1254–1254. 5 indexed citations
2.
Brito, Patricia, Ana Cristina Lima Leite, Adson Ferreira da Rocha, et al.. (2024). Avaliação do uso de nanotecnologia na quimioterapia neoadjuvante para o câncer de mama: uma revisão de evidências e classificação GRADE. Brazilian Journal of Health Review. 7(9). e74324–e74324.
3.
Chaves-Conde, Manuel, et al.. (2024). Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?. Critical Reviews in Oncology/Hematology. 202. 104454–104454. 5 indexed citations
4.
Chaves-Conde, Manuel, et al.. (2024). Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract. World Journal of Gastrointestinal Oncology. 16(4). 1166–1179. 3 indexed citations
5.
Chaves-Conde, Manuel, et al.. (2023). Neoplastic appendiceal mucinous lesions: a narrative review of the literature from an oncologist’s perspective. Clinical & Translational Oncology. 26(6). 1287–1299. 1 indexed citations
6.
Chaves-Conde, Manuel, et al.. (2020). Lenvatininb as Treatment for Naïve Patients with Aggressive Thyroid Cancer Bone Metastases and Bad Performance Status. SHILAP Revista de lepidopterología. 2020. 1–4. 3 indexed citations
7.
Fernández-Parra, E., et al.. (2019). Perioperative FLOT experience: pathological regression and toxicity. Annals of Oncology. 30. iv41–iv41.
8.
9.
Miguel, Maria J. de, Manuel Chaves-Conde, & Amancio Carnero. (2016). A genetic view of laryngeal cancer heterogeneity. Cell Cycle. 15(9). 1202–1212. 21 indexed citations
10.
Miguel, Maria J. de, Manuel Chaves-Conde, Isabel Tirado, et al.. (2016). Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival. Oncotarget. 7(22). 31723–31737. 14 indexed citations
11.
García‐Alfonso, Pilar, Manuel Chaves-Conde, Andrés Muñoz, et al.. (2015). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 15(1). 327–327. 10 indexed citations
12.
Molina‐Pinelo, Sonia, Amancio Carnero, Fernando Rivera, et al.. (2014). MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer. 14(1). 656–656. 67 indexed citations
13.
Carnero, Amancio, Aurora Astudillo, José Palacios, et al.. (2014). Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients. Human Pathology. 45(12). 2437–2446. 14 indexed citations
14.
Carrato, Alfredo, P. Escudero, Manuel Chaves-Conde, et al.. (2013). Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical & Translational Oncology. 15(9). 705–711. 7 indexed citations
15.
Alfonso, Pilar, Manuel Chaves-Conde, Andrés Muñoz, et al.. (2013). Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology. 31(4_suppl). 501–501. 1 indexed citations
16.
Carrato, Alfredo, Manuel Chaves-Conde, E. Marcuello, et al.. (2010). Panitumumab plus irinotecan, both given every 3 weeks (Q3W), as second-line treatment for irinotecan-naïve metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 28(15_suppl). e14025–e14025. 1 indexed citations
17.
Sastre, Javier, Enrique Aranda, Bartomeu Massutí, et al.. (2008). Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study. Critical Reviews in Oncology/Hematology. 70(2). 134–144. 40 indexed citations
18.
Galán, José Jorge, Manuel Chaves-Conde, Cláudia Roberta de Castro Moreno, et al.. (2007). Analysis of CXCL12 3'UTR G>A polymorphism in colorectal cancer. Oncology Reports. 18(6). 1583–7. 20 indexed citations
19.
20.
Borrega, Pablo, et al.. (2004). Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 22(1). 32–35. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by М. В. Копп Breakdown of academic impact, for papers by Jiansheng Li Breakdown of academic impact, for papers by Quanren Wang Breakdown of academic impact, for papers by Julian Adlard Breakdown of academic impact, for papers by Annett Maderer Breakdown of academic impact, for papers by Jean Philippe Metges Breakdown of academic impact, for papers by Lingzhi Hong Breakdown of academic impact, for papers by A Fujioka Breakdown of academic impact, for papers by Tommasina Biscotti Breakdown of academic impact, for papers by Soetkin Vlassak
Rankless by CCL
2026